A systematic review on the possible role of microRNA-155 in cancer treatment
- 1Medical Biotechnology Lab, Faculty of Allied and Healthcare Sciences, Chettinad Academy of Research and Education, Chettinad Hospital and Research Institute
- 2Foundation for Biology and Regenerative Medicine, Tissue Engineering and Signaling – T.E.S. (ETS)
- 3Department of Neuroscience, Section of Human Anatomy, University of Padua
Abstract
Background: Overexpression of microRNA-155 (miR-155) has been associated with cancer development, metastasis, and possible drug resistance. This systematic review analyzed the evidence from the existing literature on miR-155 expression in cancer patients undergoing treatment.
Methods: A thorough literature search was conducted in databases and search engines (ProQuest, PubMed, and Google Scholar) from January 2019 to December 2024 to identify clinical evidence on miR-155 expression in cancer treatments. To assess miR-155 expression in relation to clinical outcomes, we included 15 cancers in this systematic review. Following the PRISMA 2020 guidelines, three independent reviewers selected, extracted, and assessed the data against the predefined inclusion criteria, and a fourth reviewer verified the assessments and resolved discrepancies.
Results: Of the 15 cancers analyzed, 19 eligible studies covering eight cancers were identified and included in the review, namely breast cancer, non-small cell lung cancer, pediatric acute lymphoblastic leukemia, cutaneous melanoma, non-muscle-invasive bladder cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma, and diffuse large B-cell lymphoma. Screening and evaluation of these 19 studies showed that miR-155 expression varied by cancer type, treatment strategy, and patient sample type. While most studies associated miR-155 overexpression with treatment resistance, a few reported an association between elevated miR-155 expression and enhanced treatment sensitivity. A limitation of this study is that the search for studies reporting miR-155 expression in relation to therapeutic outcomes in patients with cancer was restricted to three databases and a 5-year timeframe.
Conclusion: Overall, the results of this study indicate that the prognostic and predictive significance of miR-155 warrants further evaluation.
Systematic Review Registration: PROSPERO ID, CRD42025632573.
Related
- Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials
- Perioperative Antifibrotic Treatment and Early Postoperative Outcomes in Patients With Idiopathic Pulmonary Fibrosis Undergoing Lung Cancer Surgery: A Systematic Review and Meta‐Analysis
- Local ablative treatment for oligoprogression during immunotherapy in metastatic non-small-cell lung cancer: a systematic review and meta-analysis
- Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis
- Patients' experience of using online interventions for the management of late effects following completion of cancer treatment-protocol for a qualitative systematic review.
BibTeX
@article{ravichandran2026systematic,
title = {{A systematic review on the possible role of microRNA-155 in cancer treatment}},
author = {Shruthi Nagainallur Ravichandran and Antara Banerjee and Pier Paolo Parnigotto and Surajit Pathak and Silvia Barbon},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1885427},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1885427/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A systematic review on the possible role of microRNA-155 in cancer treatment
AU - Shruthi Nagainallur Ravichandran
AU - Antara Banerjee
AU - Pier Paolo Parnigotto
AU - Surajit Pathak
AU - Silvia Barbon
PY - 2026
DA - 2026/10/20
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1885427
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1885427/full
AB - Background: Overexpression of microRNA-155 (miR-155) has been associated with cancer development, metastasis, and possible drug resistance. This systematic review analyzed the evidence from the existing literature on miR-155 expression in cancer patients undergoing treatment. Methods: A thorough literature search was conducted in databases and search engines (ProQuest, PubMed, and Google Scholar) from January 2019 to December 2024 to identify clinical evidence on miR-155 expression in cancer treatments. To assess miR-155 expression in relation to clinical outcomes, we included 15 cancers in this systematic review. Following the PRISMA 2020 guidelines, three independent reviewers selected, extracted, and assessed the data against the predefined inclusion criteria, and a fourth reviewer verified the assessments and resolved discrepancies. Results: Of the 15 cancers analyzed, 19 eligible studies covering eight cancers were identified and included in the review, namely breast cancer, non-small cell lung cancer, pediatric acute lymphoblastic leukemia, cutaneous melanoma, non-muscle-invasive bladder cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma, and diffuse large B-cell lymphoma. Screening and evaluation of these 19 studies showed that miR-155 expression varied by cancer type, treatment strategy, and patient sample type. While most studies associated miR-155 overexpression with treatment resistance, a few reported an association between elevated miR-155 expression and enhanced treatment sensitivity. A limitation of this study is that the search for studies reporting miR-155 expression in relation to therapeutic outcomes in patients with cancer was restricted to three databases and a 5-year timeframe. Conclusion: Overall, the results of this study indicate that the prognostic and predictive significance of miR-155 warrants further evaluation. Systematic Review Registration: PROSPERO ID, CRD42025632573.
SN - 1663-9812
ER -